Fiorella Marcheselli

Fiorella Marcheselli

Auto-generated profile, based on publicly available information

Fiorella Marcheselli

Center of Clinical Pathology and Innovative Therapy, IRCCS INRCA, 60121 Ancona, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994 in Life Sciences
Verified
Journal Article
Closed access
CPCarlo Pieri
Carlo Pieri
MMMaurizio Marra
Maurizio Marra
FMFausto Moroni
Fausto Moroni
RRRina Recchioni
Rina Recchioni
FMFiorella Marcheselli
Fiorella Marcheselli

1 November 2012 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
FOFabiola Olivieri
Fabiola Olivieri
LSLiana Spazzafumo
Liana Spazzafumo
GSGabriele Santini
Gabriele Santini
RLRaffaella Lazzarini
Raffaella Lazzarini
Maria Cristina AlbertiniMaria Cristina Albertini
Maria Cristina Albertini
APAntonio Domenico Procopio
Antonio Domenico Procopio

13 June 2012 in AGE
Verified
Journal Article
Closed access
PDF file
FOFabiola Olivieri
Fabiola Olivieri
RLRaffaella Lazzarini
Raffaella Lazzarini
RRRina Recchioni
Rina Recchioni
FMFiorella Marcheselli
Fiorella Marcheselli
Maria RippoMaria Rippo
Maria Rippo
APAntonio Domenico Procopio
Antonio Domenico Procopio

18 February 2020 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
EMEmanuela Mensà
Emanuela Mensà
Michele GuesciniMichele Guescini
Michele Guescini
AGAngelica Giuliani
Angelica Giuliani
MBMaria Giulia Bacalini
Maria Giulia Bacalini
DRDeborah Ramini
Deborah Ramini
FOFabiola Olivieri
Fabiola Olivieri
The role of epigenetics in endothelial cell senescence is a cutting‐edge topic in ageing research. However, little is known of the relative contribution to pro‐senescence signal propagation provided by microRNAs shuttled by extracellular vesicles (EVs) released from senescent cells. Analysis of microRNA and DNA methylation profiles in non‐senescent (control) and senescent (SEN) human umbilical vein endothelial cells (HUVECs), and microRNA profiling of their cognate small EVs (sEVs) and large EVs demonstrated that SEN cells released a significantly greater sEV number than control cells. sEVs were enriched in miR‐21‐5p and miR‐217, which target DNMT1 and SIRT1. Treatment of control cells with SEN sEVs induced a miR‐21/miR‐217‐related impairment of DNMT1‐SIRT1 expression, the reduction of proliferation markers, the acquisition of a senescent phenotype and a partial demethylation of the locus encoding for miR‐21. MicroRNA profiling of sEVs from plasma of healthy subjects aged 40–100 years showed an inverse U‐shaped age‐related trend for miR‐21‐5p, consistent with senescence‐associated biomarker profiles. Our findings suggest that miR‐21‐5p/miR‐217 carried by SEN sEVs spread pro‐senescence signals, affecting DNA methylation and cell replication.

19 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
FOFabiola Olivieri
Fabiola Olivieri
LSLiana Spazzafumo
Liana Spazzafumo
MBMassimiliano Bonafè
Massimiliano Bonafè
RRRina Recchioni
Rina Recchioni
FPFrancesco Prattichizzo
Francesco Prattichizzo
ABAnna Rita Bonfigli
Anna Rita Bonfigli
MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications

1 September 2014 in Aging
Verified
Journal Article
Open access
FOFabiola Olivieri
Fabiola Olivieri
MBMassimiliano Bonafè
Massimiliano Bonafè
LSLiana Spazzafumo
Liana Spazzafumo
MGMirko Gobbi
Mirko Gobbi
FPFrancesco Prattichizzo
Francesco Prattichizzo
RTRoberto Testa
Roberto Testa
Circulating miR-126-3p levels were determined in 136 healthy subjects (CTRs) aged 20-90 years and 193 patients with type-2 diabetes mellitus (T2DMs) aged 40-80 years, to explore the combined effect of age and glycemic state on miR-126-3p expression. Moreover, intra/extracellular miR-126-3p levels were measured in human endothelial cells (HUVECs) undergoing senescence under normo/hyper-glycemic conditions. Plasma miR-126-3p was significantly higher in the oldest compared with the youngest CTRs ( 75 years; relative expression: 0.27±0.29 vs. 0.48±0.39, p=0.047). Age-based comparison between CTRs and T2DM demonstrated significantly different miR-126-3p levels only in the oldest (0.48±0.39 vs. 0.22±0.23, p<0.005). After multiple adjustments, miR-126-3p levels were seen to be lower in patients with poor glycemic control, compared with age-matched CTRs. The age-related increase in plasma miR-126-3p found in CTRs was paralleled by a 5/6-fold increase in intra/extracellular miR-126-3p in in vitro-cultured HUVECs undergoing senescence. Notably, significant down- regulation of SPRED-1 protein, a validated miR-126-3p target, was found in senescent HUVECs. Moreover, miR-126-3p expression was down-regulated in intermediate-age HUVECs grown in high-glucose medium until senescence. Aging/senescence-associated miR-126-3p up-regulation is likely a senescence-associated compensatory mechanism that is blunted when endothelial cells are exposed to high glucose levels, a phenomenon that probably occurs in vivo in T2DM patients.